# Bio-Kidney AI 2026: Implementation Protocol
## From Computational Validation to Fabrication-Ready Specification

**Author:** Carlos David Moreno Caceres
**Affiliation:** Independent Researcher — VirtusSapiens, Medellin, Colombia
**ORCID:** 0009-0005-3933-5072
**DOI (Preprint):** 10.5281/zenodo.19508077
**Version:** 1.0 — April 2026

---

> **Purpose of this document:**
> This protocol translates the computational outputs of Bio-Kidney AI 2026
> into laboratory-executable fabrication instructions. It is intended for
> bioengineering laboratories equipped with extrusion-based bioprinters
> capable of multi-material deposition and pressure control in the range
> of 20-120 Pa. Each section derives directly from validated simulation
> outputs and provides actionable parameters for each fabrication step.

---

## Layer 1: Vascular Architecture to Bioink Specification

### 1.1 Design Rationale

The CCO v8 algorithm generates 1,902 vascular segments distributed across
12 hierarchical levels (0-11), with radii ranging from 500 um at the main
renal artery to 38 um at terminal arterioles. Each hierarchical level
corresponds to a distinct anatomical vessel class, with specific mechanical
and biological requirements that must be matched by the bioink formulation.

The fundamental principle is: **vessel radius determines wall shear stress,
which determines the mechanical demand on the bioink, which determines
its optimal formulation.**

Wall shear stress at each level was estimated from Poiseuille flow:
  tau = (4 * eta * Q) / (pi * r^3)
where eta = 3.5e-3 Pa*s, Q is Murray-scaled flow, and r is mean radius.

### 1.2 Vascular Zone Classification

Based on the CCO v8 hemodynamic data (Table S2, Supplementary Material),
the 12 levels are grouped into 4 fabrication zones:

---

#### ZONE A — Large Conductance Vessels (Levels 0-2)
**Anatomical correlate:** Main renal artery, segmental arteries, lobar arteries
**Radius range:** 271-500 um
**Mean pressure:** 87-100 mmHg
**Wall shear stress:** High (>15 dyn/cm2)
**Segment count:** 13 segments (0.7% of total)

**Bioink Specification — Zone A:**
| Parameter | Value | Rationale |
|-----------|-------|-----------|
| Base material | GelMA 12% + Alginate 2.5% | High stiffness for large vessel integrity |
| Nanocellulose | 1.2% CNC | Reinforcement for pressure resistance |
| Crosslinker | CaCl2 100 mM + UV 365nm 30s | Dual crosslinking for mechanical stability |
| Yield stress (tau_y) | 85-120 Pa | Herschel-Bulkley fit for extrusion |
| Extrusion pressure | 90-110 Pa | Co-SWIFT optimal zone |
| Nozzle diameter | 400-600 um | Matched to vessel caliber |
| Print temperature | 22 degrees C | GelMA below gelation point |
| Cell density | 5e6 cells/mL endothelial (HUVEC) | Lumenization requirement |
| Post-print crosslink | CaCl2 50 mM bath, 5 min | Stabilization |

**Quality checkpoint:** Burst pressure test > 120 mmHg before proceeding.

---

#### ZONE B — Distributing Vessels (Levels 3-5)
**Anatomical correlate:** Interlobar, arcuate, interlobular arteries
**Radius range:** 104-296 um
**Mean pressure:** 67-81 mmHg
**Wall shear stress:** Moderate (8-15 dyn/cm2)
**Segment count:** 228 segments (12.0% of total)

**Bioink Specification — Zone B:**
| Parameter | Value | Rationale |
|-----------|-------|-----------|
| Base material | GelMA 9% + Alginate 2.0% | Moderate stiffness, better cell viability |
| Nanocellulose | 0.9% CNC | Moderate reinforcement |
| Crosslinker | CaCl2 75 mM + UV 365nm 20s | Slightly softer matrix |
| Yield stress (tau_y) | 55-85 Pa | Reduced resistance for smaller nozzles |
| Extrusion pressure | 70-90 Pa | Co-SWIFT Pareto optimal range |
| Nozzle diameter | 200-400 um | Matched to vessel caliber |
| Print temperature | 22 degrees C | Maintained below gelation |
| Cell density | 8e6 cells/mL (HUVEC + SMC 3:1) | Smooth muscle for vasoregulation |
| Post-print crosslink | CaCl2 50 mM bath, 5 min | Stabilization |

**Quality checkpoint:** Perfusion test at 80 mmHg, leakage < 5% at 10 min.

---

#### ZONE C — Pre-glomerular Arterioles (Levels 6-8)
**Anatomical correlate:** Afferent arterioles, distal afferent arterioles,
pre-glomerular arterioles
**Radius range:** 50-175 um
**Mean pressure:** 50-61 mmHg
**Wall shear stress:** High (>20 dyn/cm2) — critical zone for filtration
**Segment count:** 564 segments (29.7% of total)
**CRITICAL:** Terminal pressures must exceed 43 mmHg for Starling filtration

**Bioink Specification — Zone C:**
| Parameter | Value | Rationale |
|-----------|-------|-----------|
| Base material | GelMA 7% + Alginate 1.5% | Optimized for cell viability at high shear |
| Nanocellulose | 0.8% CNC | NICE bioink standard formulation |
| Crosslinker | LAP 0.25% + UV 405nm 15s | Visible light crosslinking, cell-compatible |
| Yield stress (tau_y) | 35-60 Pa | Co-SWIFT validated range (v8 simulation) |
| Extrusion pressure | 55-70 Pa | 98% viability at this range (Pareto output) |
| Nozzle diameter | 100-200 um | Precision deposition required |
| Print temperature | 20 degrees C | Slightly cooler for finer resolution |
| Cell density | 15e6 cells/mL (podocytes + HUVEC 1:2) | Glomerular interface preparation |
| Post-print crosslink | LAP UV bath 405nm, 10s | Minimal UV exposure for cell safety |

**Quality checkpoint:** Pressure hold at 58 mmHg for 30 min.
Verify zero leakage at glomerular interface nodes.

---

#### ZONE D — Terminal Arterioles and Glomerular Interface (Levels 9-11)
**Anatomical correlate:** Terminal arterioles, pre-glomerular sphincters
**Radius range:** 38-92 um
**Mean pressure:** 43-55 mmHg (floor: 43 mmHg)
**Wall shear stress:** Variable, regulated by myogenic response
**Segment count:** 100 segments (5.3% of total)
**CRITICAL ZONE:** These are the filtration entry points.
1,300 glomerular demand seeds are located at terminals of this zone.

**Bioink Specification — Zone D:**
| Parameter | Value | Rationale |
|-----------|-------|-----------|
| Base material | GelMA 5% + Fibrin 2 mg/mL | Soft matrix for glomerular compliance |
| Growth factors | VEGF 50 ng/mL + EGF 20 ng/mL | Angiogenesis induction post-print |
| Crosslinker | Thrombin 2 U/mL (fibrin) + LAP UV | Sequential crosslinking |
| Yield stress (tau_y) | 15-35 Pa | Minimal resistance for delicate structures |
| Extrusion pressure | 30-50 Pa | Below cytotoxic shear threshold |
| Nozzle diameter | 50-100 um | Highest precision required |
| Print temperature | 18 degrees C | Maximum resolution |
| Cell density | 20e6 cells/mL (podocytes primary) | Glomerular filtration barrier |
| Post-print | Fibrin gelation 37 degrees C, 30 min | Physiological gelation |

**Quality checkpoint:** GFR spot-test (single glomerular unit):
target 0.1 uL/min/glomerulus = 100 mL/min for 1e6 glomeruli.

---

### 1.3 Bioink Transition Protocol

At zone boundaries, abrupt bioink transitions create mechanical stress
concentrations that can cause delamination. A gradient transition layer
is required at each zone interface:

**Zone A-B interface (271 um boundary):**
- 3 layers of GelMA 10.5% + Alginate 2.25% (intermediate formulation)
- Layer thickness: 50 um per layer
- Extrusion pressure: 80 Pa

**Zone B-C interface (104 um boundary):**
- 2 layers of GelMA 8% + Alginate 1.75% + CNC 0.85%
- Layer thickness: 30 um per layer
- Extrusion pressure: 62 Pa

**Zone C-D interface (50 um boundary):**
- 1 layer of GelMA 6% + Fibrin 1 mg/mL
- Layer thickness: 20 um
- Extrusion pressure: 40 Pa

---

### 1.4 Cortical vs. Medullary Deposition Strategy

The Beta(3,1.2) demand distribution of CCO v8 places 63.1% of glomerular
demand in the cortical zone (normalized radius > 0.60). This asymmetry
requires a spatially-aware deposition strategy:

**Cortical region (outer 40% of kidney volume):**
- Dominant zone: C and D bioinks
- Print speed: 8 mm/s (higher resolution required)
- Layer height: 50 um
- Expected glomerular density: ~820 units/cm3

**Medullary region (inner 60% of kidney volume):**
- Dominant zone: A and B bioinks
- Print speed: 12 mm/s (lower resolution acceptable)
- Layer height: 100 um
- Expected tubular density: ~240 units/cm3

**Transition zone (normalized radius 0.55-0.65):**
- Mixed deposition: alternating C and B layers
- Print speed: 10 mm/s
- Layer height: 75 um

---

### 1.5 Data Interface: CCO v8 to Bioprinter

The CCO v8 algorithm exports `renal_data_v1.json` containing per-segment
coordinates, diameters, and pressures. The following mapping translates
this data to bioprinter G-code parameters:

```python
# Zone assignment by radius
def assign_zone(radius_um):
    if radius_um >= 271:
        return 'A'  # GelMA 12% + Alginate 2.5%
    elif radius_um >= 104:
        return 'B'  # GelMA 9% + Alginate 2.0%
    elif radius_um >= 50:
        return 'C'  # GelMA 7% + Alginate 1.5% (NICE)
    else:
        return 'D'  # GelMA 5% + Fibrin 2 mg/mL

# Extrusion pressure by zone (Pa)
ZONE_PRESSURE = {'A': 100, 'B': 80, 'C': 62, 'D': 40}

# Nozzle diameter by zone (um)
ZONE_NOZZLE = {'A': 500, 'B': 300, 'C': 150, 'D': 75}
```

This function can be applied directly to the `arbol_vascular_cco_v8.csv`
to generate a zone-tagged deposition schedule for any multi-material
extrusion bioprinter.

---


### 1.6 Critical Corrections (Peer Review — April 2026)

The following parameters were identified as missing from the initial
Layer 1 specification following independent review:

#### 1.6.1 Thermal Re-equilibration Time Between Zone Transitions

When switching bioink cartridges between zones (e.g., Zone B at 22C to
Zone C at 20C), the nozzle assembly requires thermal stabilization before
deposition resumes. Insufficient stabilization causes viscosity gradients
at the nozzle tip, leading to inconsistent extrusion and potential clogging.

| Transition | Temperature change | Re-equilibration time | Verification method |
|------------|-------------------|----------------------|---------------------|
| A to B | 22C to 22C | 30 seconds | Extrude 5 uL test drop |
| B to C | 22C to 20C | 90 seconds | Thermocouple at nozzle tip |
| C to D | 20C to 18C | 120 seconds | Thermocouple + test extrusion |
| Any reversal | Lower to higher T | 60 seconds | Test drop only |

**Protocol:** After each zone transition, extrude 10 uL of bioink onto
a sacrificial substrate before resuming kidney deposition. Discard if
the drop morphology deviates > 15% from the expected diameter.

#### 1.6.2 GelMA Swelling Compensation Factor

GelMA hydrogels absorb water post-crosslinking and expand volumetrically.
This swelling must be pre-compensated in the print file, especially in
Zone D where vessel lumens are 38-92 um — a 10% swelling would reduce
a 50 um lumen to 45 um, potentially occluding flow.

Measured swelling indices by GelMA concentration (from literature):

| GelMA % | Swelling index (24h in PBS, 37C) | Lumen compensation factor |
|---------|----------------------------------|--------------------------|
| 12% (Zone A) | 1.08 (8% expansion) | Print at 108% nominal diameter |
| 9% (Zone B) | 1.12 (12% expansion) | Print at 112% nominal diameter |
| 7% (Zone C) | 1.18 (18% expansion) | Print at 118% nominal diameter |
| 5% (Zone D) | 1.24 (24% expansion) | Print at 124% nominal diameter |

**Implementation:** Apply compensation factor to the CCO v8 radius data
before G-code generation:

```python
SWELLING_FACTOR = {'A': 1.08, 'B': 1.12, 'C': 1.18, 'D': 1.24}

def compensated_radius(radius_um, zone):
    return radius_um * SWELLING_FACTOR[zone]
```

#### 1.6.3 Sacrificial Bioink (Pluronic F-127) — Lumen Evacuation Protocol

Co-SWIFT requires a sacrificial material to occupy vessel lumens during
printing, which is subsequently removed to create patent channels. Pluronic
F-127 is the standard sacrificial bioink due to its reversible thermal
gelation: liquid below 4C, gel above 10C.

**Pluronic F-127 specification:**
| Parameter | Value |
|-----------|-------|
| Concentration | 35% w/v in PBS |
| Print temperature | 22-24C (gel state, supports structure) |
| Removal temperature | 4C (liquid state, flows out) |
| Removal method | Cold PBS perfusion at 4C, 10 min |
| Flow rate for removal | 0.5 mL/min per vessel inlet |
| Verification | Fluorescent dye perfusion (FITC-dextran 70 kDa) |

**Lumen evacuation sequence (v1.1 — corrected):**

CRITICAL: Do NOT transfer directly from 37C to 4C. Thermal shock causes
GelMA contraction and microfractures at zone interfaces.

Controlled thermal gradient protocol:
1. Reduce incubator from 37C to 22C over 20 minutes (0.75C/min)
2. Hold at 22C for 10 minutes (Pluronic begins softening)
3. Reduce from 22C to 10C over 15 minutes (0.8C/min)
4. Hold at 10C for 5 minutes
5. Reduce from 10C to 4C over 5 minutes (1.2C/min)
6. Total cooling time: ~55 minutes

Perfusion protocol (pressure-controlled — NEVER exceed 43 mmHg):
- Connect inlet (Zone A vessel) to pressure-controlled syringe pump
- Load with cold PBS 4C supplemented with Penicillin/Streptomycin 1%
- Set maximum perfusion pressure: 35 mmHg (safety margin below 43 mmHg)
- Flow rate: 0.3 mL/min initial (gravity-assisted preferred)
- Duration: 30-60 minutes depending on construct size
- Monitor outlet flow rate — if flow stops, DO NOT increase pressure
  (indicates blockage — see troubleshooting below)

Hydraulic water hammer prevention:
- Never apply sudden pressure changes at any zone junction
- All pressure ramps must be gradual: maximum 5 mmHg per 30 seconds
- If Pluronic viscosity causes resistance: wait 10 additional minutes
  at 4C before retrying — do not compensate with higher pressure

Troubleshooting:
- No flow at Zone B outlet: Pluronic incompletely liquefied — extend
  cooling time 15 minutes and retry
- No flow at Zone C outlet: Potential blockage — reduce pressure to
  20 mmHg and perfuse for additional 20 minutes
- Zone D terminals not reached: Repeat full evacuation sequence once
  If second attempt fails, construct is non-viable for filtration

Patency verification:
- Inject FITC-dextran 70 kDa in PBS at 30 mmHg input pressure
- Target: fluorescent signal in >90% of Zone D terminals within 5 min
- >85% acceptable (literature standard, Jennifer Lewis Harvard group)
- <85%: construct fails Zone C bottleneck — do not proceed to maturation

**Critical note — Zone C bottleneck:**
Zone C is the pressure-critical gateway. Any blockage here drops terminal
pressures below 43 mmHg, eliminating Starling filtration regardless of
bioink or cell quality. Monitor outlet flow continuously during evacuation.
A sudden pressure increase at the inlet when outlet flow stops indicates
a hydraulic water hammer risk — stop immediately and allow 10 minutes
passive equilibration before retrying.

---

## Layer 2: Co-SWIFT Bioprinting Protocol by Zone

### 2.1 Overview

Layer 2 translates the 100 Pareto-optimal bioprinting solutions from the
Co-SWIFT optimization module into a zone-specific deposition protocol.
The optimization balanced two competing objectives: maximizing post-print
cell viability and minimizing extrusion pressure. The selected operating
point achieves 98% viability at 60 Pa mean extrusion pressure.

The critical constraint for this layer is the Zone C bottleneck identified
in peer review: terminal pressures in pre-glomerular arterioles must exceed
43 mmHg at all times. This constraint propagates backward — if Zone C
vessels are not patent, the 115.2 mL/min GFR prediction is invalid.

### 2.2 Print Sequence Strategy

The kidney is printed in a specific sequence to ensure structural integrity
and prevent zone collapse:

**Phase 1 — Structural scaffold (Days 1-2 of fabrication):**
Print the medullary core first (Zone A and B vessels) to establish the
load-bearing architecture. The kidney cannot support its own weight during
printing without this scaffold in place first.

Sequence:
1. Print Zone A vessels (13 segments) — main conductance tree
2. Allow CaCl2 crosslinking: 100 mM bath, 10 minutes
3. UV crosslink: 365 nm, 30 seconds
4. Print Zone B vessels (228 segments) — distributing tree
5. Allow CaCl2 crosslinking: 75 mM bath, 8 minutes
6. UV crosslink: 365 nm, 20 seconds

**Phase 2 — Cortical vascularization (Days 2-3 of fabrication):**
Print cortical zones C and D in interleaved layers to maintain spatial
registration with Zone B terminals.

Sequence:
1. Print Zone C arterioles (564 segments) — cortical layer by layer
2. Thermal re-equilibration: 90 seconds at 20C
3. LAP UV crosslink: 405 nm, 15 seconds per layer
4. Print Zone D terminals (100 segments) — glomerular interface
5. Thermal re-equilibration: 120 seconds at 18C
6. Fibrin gelation: 37C incubation, 30 minutes

**Phase 3 — Pluronic evacuation (Day 3):**
Execute lumen evacuation protocol (Section 1.6.3) before any cell
seeding or maturation steps.

### 2.3 Layer-by-Layer Deposition Parameters

The kidney is sliced into horizontal layers for deposition. Layer height
varies by zone to match the resolution requirements:

| Region | Layer height | Print speed | Infill pattern | Overlap |
|--------|-------------|-------------|----------------|---------|
| Medullary core | 100 um | 12 mm/s | Concentric | 15% |
| Medullary-cortical transition | 75 um | 10 mm/s | Grid | 20% |
| Cortical (Zone C) | 50 um | 8 mm/s | Concentric | 25% |
| Glomerular interface (Zone D) | 25 um | 5 mm/s | Radial | 30% |

**Total estimated print time:** 18-24 hours for a full kidney construct
(11 x 6 x 5 cm) on a multi-nozzle bioprinter.

**Cell viability during extended print — critical consideration:**
Maintaining cells in bioink cartridges for 18-24 hours at 22C causes
progressive metabolic stress and viability decline. Two mitigation
strategies are recommended:

Option A — Segmented printing (preferred):
- Print Zone A and B vessels on Day 1 (scaffold only, no cells)
- Refrigerate construct at 4C overnight
- Cell-seed Zones A and B by perfusion on Day 2 morning
- Print Zones C and D with cells on Day 2 (6-8 hours, cells fresh)
- Advantage: cells never spend more than 8 hours in cartridge

Option B — Active cartridge refrigeration:
- Maintain bioink cartridges at 4C during printing
- Warm to print temperature only at nozzle tip (heated nozzle cap)
- Slows cell metabolism, extends viability window to 18-20 hours
- Requires bioprinter with independently temperature-controlled cartridges

### 2.4 Pareto Front Operating Points by Zone

The Co-SWIFT optimization identified 100 Pareto-optimal solutions. From
these, the zone-specific operating points are selected as follows:

**Selection criterion:** Maximum viability subject to extrusion pressure
remaining within the bioprinter hardware limits (20-120 Pa).

| Zone | Selected Pareto point | Extrusion P (Pa) | Viability (%) | Shear stress (dyn/cm2) |
|------|--------------------|-----------------|---------------|------------------------|
| A | Point #8 | 100 | 95.2 | 4.8 |
| B | Point #23 | 80 | 96.8 | 5.1 |
| C | Point #47 | 62 | 98.0 | 5.6 |
| D | Point #71 | 40 | 98.9 | 3.2 |

**Note on Zone C:** Pareto point #47 (62 Pa, 98% viability) was selected
as the primary operating point for Zone C because it represents the
validated optimum from the Co-SWIFT simulation. However, if the bioprinter
pressure sensor reads below 58 Pa at Zone C nozzle tips, STOP and verify
Pluronic evacuation — incomplete lumen clearance increases back-pressure
and forces the operator to compensate with higher extrusion pressure,
which reduces viability below the 95% threshold.

### 2.5 Multi-Material Print Head Configuration

For a full kidney construct, the bioprinter requires simultaneous access
to at least 5 materials:

| Cartridge | Material | Volume required | Storage temperature |
|-----------|----------|-----------------|---------------------|
| 1 | Zone A bioink (GelMA 12%) | 8 mL | 4C until use |
| 2 | Zone B bioink (GelMA 9%) | 35 mL | 4C until use |
| 3 | Zone C bioink (GelMA 7% NICE) | 85 mL | 4C until use |
| 4 | Zone D bioink (GelMA 5% + Fibrin) | 15 mL | Prepare fresh, use within 2h |
| 5 | Pluronic F-127 35% | 50 mL | 22C during printing |

**Total bioink volume:** ~193 mL per kidney construct.

### 2.6 Real-Time Quality Monitoring During Print

The following parameters must be monitored continuously during printing:

| Parameter | Acceptable range | Action if out of range |
|-----------|-----------------|----------------------|
| Extrusion pressure | Zone-specific +/- 5 Pa | Pause, recalibrate nozzle |
| Print temperature | Target +/- 0.5C | Thermal re-equilibration |
| Layer registration | < 10 um XY deviation | Recalibrate Z-axis |
| Bioink viscosity (rheometer) | Zone-specific +/- 10% | Replace cartridge |
| Cell viability (spot check) | > 90% (trypan blue) | Pause, assess bioink age |

**Recommended monitoring interval:** Every 2 hours or every 500 deposited
segments, whichever comes first.

### 2.7 Post-Print Structural Assessment

Before proceeding to Layer 3 (iPSC maturation), the printed construct
must pass the following structural checkpoints:

1. **Gross morphology:** Kidney outline within 5% of target dimensions
   (11 x 6 x 5 cm). Verify with calipers.

2. **Lumen patency (Zone A-B):** Perfuse with PBS at 80 mmHg.
   No visible leakage at anastomoses after 10 minutes.

3. **Zone C bottleneck verification (CRITICAL):**
   Perfuse with FITC-dextran 70 kDa at 58 mmHg input pressure.
   Fluorescent signal must reach > 90% of Zone D terminal nodes
   within 5 minutes. Failure here means Pluronic evacuation was
   incomplete — repeat evacuation protocol before proceeding.

4. **Mechanical integrity:** Gentle compression test.
   Construct must recover > 80% of original dimensions after
   20% strain. Failure indicates insufficient crosslinking.

5. **Cell viability post-print:** Confocal imaging of 3 random
   cross-sections. Live/dead staining target: > 90% viable cells
   in all zones.

---


---

## Layer 3: iPSC Differentiation to Maturation Schedule

### 3.1 Overview

Layer 3 translates the computational iPSC differentiation kinetics model
(Takasato 2015 protocol, 30-day simulation) into a laboratory maturation
schedule. The simulation predicts full phenotypic purity across three
renal lineages by day 21, with OCT4 residual below 0.1%. This layer
converts those predictions into actionable culture conditions, media
changes, and verification checkpoints.

The printed construct at this stage has patent lumens (verified by
FITC-dextran), structural integrity (passed Layer 2 checkpoints), but
contains cells that have not yet differentiated into their final renal
phenotypes. Maturation is the process by which iPSCs and progenitor
cells become functional podocytes, proximal tubule cells, and loop of
Henle cells under controlled biochemical and mechanical stimulation.

### 3.2 Pre-Maturation Requirements

Before initiating the maturation protocol, verify:

| Requirement | Verification method | Minimum threshold |
|-------------|--------------------|--------------------|
| Lumen patency | FITC-dextran perfusion | >90% Zone D terminals |
| Cell viability post-print | Live/dead confocal | >90% viable |
| Structural integrity | Compression test | >80% shape recovery |
| Sterility | Culture medium turbidity | No turbidity at 48h |
| OCT4 baseline | Immunofluorescence | Record initial value |

If any requirement is not met, do not proceed. The maturation protocol
cannot rescue a structurally compromised construct.

### 3.3 Bioreactor Configuration

The printed kidney construct requires perfusion culture in a closed
bioreactor system that simultaneously provides:
- Nutrient delivery via vascular perfusion
- Mechanical stimulation (pulsatile flow mimicking renal blood flow)
- Biochemical gradient (differentiation media at controlled concentration)
- Waste removal via collecting system outlet

**Recommended bioreactor parameters:**
| Parameter | Value | Rationale |
|-----------|-------|-----------|
| Perfusion flow rate | 0.5-2.0 mL/min | Renal blood flow scaled to construct |
| Inlet pressure | 80 mmHg systolic / 50 mmHg diastolic | Physiological renal artery pressure |
| Pulsation frequency | 60-80 cycles/min | Normal heart rate |
| Temperature | 37C | Physiological |
| CO2 | 5% | pH maintenance |
| O2 | 21% (normoxic) | Prevent hypoxic stress during maturation |
| Media change | Every 48 hours | Maintain growth factor concentrations |

### 3.4 Maturation Timeline — 30-Day Protocol

The simulation predicts three distinct phases of differentiation kinetics,
each requiring specific media formulations and mechanical conditions:

---

#### PHASE 1: Intermediate Mesoderm Induction (Days 1-7)
**Simulation prediction:** Rapid decline in OCT4 (pluripotency marker),
activation of OSR1 and PAX2 (intermediate mesoderm markers).
**Target by day 7:** OCT4 < 20% of baseline, PAX2 > 60% expression.

**Media formulation — Phase 1:**
| Component | Concentration | Role |
|-----------|--------------|------|
| RPMI 1640 base | Standard | Basal medium |
| B27 supplement (minus insulin) | 1x | Cell survival |
| CHIR99021 (GSK3 inhibitor) | 8 uM days 1-3, then 5 uM | WNT activation |
| FGF9 | 200 ng/mL | Mesoderm patterning |
| Heparin | 1 ug/mL | FGF9 stabilization |

**Mechanical protocol — Phase 1:**
- Perfusion: 0.5 mL/min constant (no pulsation)
- Rationale: Cells are transitioning — avoid mechanical stress

**Verification checkpoint — Day 7:**
- Immunofluorescence: PAX2+/WT1+ cells > 50% of total
- OCT4 < 25% of day 0 baseline
- No visible necrotic zones in confocal imaging
- If checkpoint fails: extend Phase 1 by 3 days with CHIR99021 at 3 uM

---

#### PHASE 2: Nephron Progenitor Expansion (Days 8-14)
**Simulation prediction:** Emergence of three distinct progenitor
populations. PAX2/WT1 double-positive cells peak at day 10-12.
**Target by day 14:** Three lineage-committed populations detectable.

**Media formulation — Phase 2:**
| Component | Concentration | Role |
|-----------|--------------|------|
| RPMI 1640 + B27 | Standard | Base |
| FGF9 | 200 ng/mL | Continued mesoderm support |
| Activin A | 10 ng/mL | Podocyte lineage bias |
| BMP7 | 25 ng/mL | Tubular lineage induction |
| VEGF-A | 50 ng/mL | Endothelial survival and migration |

**Mechanical protocol — Phase 2:**
- Perfusion: increase to 1.0 mL/min
- Begin pulsatile flow: 0.8 mL/min baseline + 0.4 mL/min pulse
- Pulse frequency: 60 cycles/min
- Rationale: Mechanical stimulation enhances nephron patterning

**Verification checkpoint — Day 14:**
- Flow cytometry: NPHS1+ (podocyte), LRP2+ (PT), UMOD+ (LoH) all detectable
- Vascular integrity: repeat FITC-dextran perfusion (>85% patency)
- Cell density: no significant reduction from post-print count
- If checkpoint fails: increase VEGF-A to 100 ng/mL for 3 additional days

---

#### PHASE 3: Terminal Differentiation and Functional Maturation (Days 15-30)
**Simulation prediction:** Phenotypic purity >95% for all three lineages
by day 15, reaching 100% by day 21. OCT4 below 0.1% by day 21.
**Target by day 21:** Full lineage commitment. Days 22-30: functional maturation.

**Media formulation — Phase 3A (Days 15-21):**
| Component | Concentration | Role |
|-----------|--------------|------|
| DMEM/F12 + B27 | Standard | Maturation base |
| Oncostatin M | 20 ng/mL | Podocyte maturation |
| Dexamethasone | 1 uM | Tubular transport induction |
| Aldosterone | 10 nM | ENaC and AQP2 expression |
| ADH (vasopressin) | 1 nM | Collecting duct maturation |
| Creatinine | 100 uM | Tubular secretion stimulus |

**Media formulation — Phase 3B (Days 22-30):**
| Component | Concentration | Role |
|-----------|--------------|------|
| DMEM/F12 + B27 | Standard | Maturation base |
| Albumin | 4 g/dL | Oncotic pressure simulation |
| Inulin | 1 mg/mL | GFR measurement marker |
| Para-aminohippurate | 50 uM | Tubular secretion marker |

**Mechanical protocol — Phase 3:**
- Perfusion: 1.5-2.0 mL/min pulsatile
- Inlet pressure: 80/50 mmHg (systolic/diastolic)
- Rationale: Full physiological pressure loading for functional adaptation

**Critical verification checkpoint — Day 21 (GO/NO-GO decision):**

This is the most important checkpoint in the entire protocol.
The simulation predicts OCT4 < 0.1% by day 21. If this is not achieved,
teratoma risk is unacceptable and the construct must be discarded.

| Marker | Target | Method | GO threshold |
|--------|--------|--------|-------------|
| OCT4 | < 0.1% | qPCR + IF | < 0.1% — NO exceptions |
| NPHS1 (podocyte) | > 95% purity | Flow cytometry | > 90% |
| LRP2 (proximal tubule) | > 95% purity | Flow cytometry | > 90% |
| UMOD (loop of Henle) | > 95% purity | Flow cytometry | > 90% |
| Ki67 (proliferation) | < 5% | Immunofluorescence | < 10% |

If OCT4 > 0.1%: DISCARD construct. Do not proceed to functional testing.
If lineage purities 85-90%: Extend Phase 3A by 5 days before re-testing.
If lineage purities < 85%: DISCARD construct.

**Final verification checkpoint — Day 30:**

| Test | Method | Target |
|------|--------|--------|
| GFR spot-test | Inulin clearance | > 80 mL/min bilateral |
| Tubular reabsorption | Glucose clearance | > 95% reabsorption |
| Albumin retention | Albumin in outflow | < 30 mg/day (normal range) |
| Electrolyte balance | Na+/K+ in outflow | Within physiological range |
| Urine output | Collect duct outflow | 1.5-2.5 L/day equivalent |

### 3.5 Simulation vs. Laboratory Correlation

The following table maps computational predictions to expected laboratory
measurements, providing a direct validation bridge between Bio-Kidney
AI 2026 and experimental results:

| Module output (simulation) | Laboratory measurement | Expected correlation |
|---------------------------|----------------------|---------------------|
| OCT4 < 0.1% by day 21 | qPCR Ct value > 35 | Direct |
| NPHS1+ purity 100% | Flow cytometry > 95% | -5% tolerance |
| GFR 115.2 mL/min | Inulin clearance | 80-120 mL/min range |
| Reabsorption 98.1% | Glucose fractional excretion | < 2% |
| Urine output 2.19 L/day | Collecting system volume | 1.8-2.5 L/day |
| PO2 minimum 5.6 mmHg | Oxygen microsensor | > 4 mmHg threshold |

**Note on GFR tolerance:** The simulation predicts 115.2 mL/min for a
construct replicating 1,300 glomerular units. A laboratory construct
with 1,300 glomerular seeds but variable cell seeding efficiency
(typically 70-85%) is expected to achieve 70-90 mL/min in first
functional tests — still within CKD Stage 1-2 range and clinically
meaningful.

---

## Status: Layers 1-3 Complete

| Layer | Title | Status |
|-------|-------|--------|
| 1 | Vascular Architecture to Bioink Specification | COMPLETE (v1.1) |
| 2 | Co-SWIFT Bioprinting Protocol by Zone | COMPLETE (v1.1) |
| 3 | iPSC Differentiation to Maturation Schedule | COMPLETE |
| 4 | Quality Control and Functional Verification | PENDING |

---
*Bio-Kidney AI 2026 — Implementation Protocol v1.2*
*Carlos David Moreno Caceres — VirtusSapiens — April 2026*
*DOI: 10.5281/zenodo.19508077*
